Veru to advance sabizabulin for pancreatic cancer resistant to daraxonrasib, ends atherosclerosis work
Veru said new preclinical data show its oral drug sabizabulin kept anticancer activity in daraxonrasib-resistant pancreatic cancer cell lines. The company will pursue a planned Phase 2b trial in that setting and will stop exploring sabizabulin for chronic inflammation tied to atherosclerotic cardiovascular disease. The filing contains no financial results, and the company says the work will need additional funding beyond its near-term enobosarm focus.
Key points
- Preclinical study conducted in August 2026 found sabizabulin had a resistance index of 0.25 in a daraxonrasib-resistant pancreatic cancer cell line, indicating increased sensitivity
- Veru plans to seek regulatory clarity from the FDA through a preIND meeting in calendar Q4 2026
- Sabizabulin intellectual property protection runs until 2043, and Veru controls global development and commercialization rights
- Company says it will prioritize internal cash for enobosarm, including the PLATEAU Phase 2b trial, so sabizabulin's pancreatic cancer work depends on securing additional funding
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.